肝细胞癌治疗诱导的衰老的可操作的异质性
Pujan Engels1,2, Andras Szolek1, Sebastian Hörner3
1Department of Innate Immunity, Institute of Immunology, University of Tübingen, Tübingen, Germany.
治疗诱导的衰老 (TIS) 在肝癌 (HCC) 暴露癌细胞免疫疗法. 衰老的HCC细胞表现出独特的抗原,使它们成为T细胞双特异性抗体和CAR NK细胞的点.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 治疗诱导的衰老 (TIS) 导致癌细胞的细胞循环停止,可能增强免疫监测.
- 肝细胞癌 (HCC) 是一种患有高死亡率的流行癌症,TIS在HCC免疫治疗中的作用尚未完全理解.
研究的目的:
- 描述TIS在HCC中的分子特征,这些特征可以被免疫疗法利用.
- 为了比较已知 (埃托波西德,阿利瑟蒂布) 和新型 (CX5461) TIS诱导剂对HCC细胞系的影响.
主要方法:
- 系统地比较TIS诱导剂 (etoposide,alisertib,CX5461) 对它们对老化相关分泌表型 (SASP),表面体和HCC细胞系的先天免疫清除的影响.
- 使用四个HCC细胞系和公共HCC数据集进行验证.
主要成果:
- 所有测试的化合物都在HCC细胞中诱导了TIS,上调转移相关抗原和免疫治疗相关抗原 (CD95,B7-H3,Her2).
- 衰老的HCC细胞变得易受T细胞参与的双特异性抗体和CAR NK细胞的向.
结论:
- 衰老的HCC细胞的异质但特定的特征可以通过不同的免疫治疗策略得到利用.
- 在HCC中,TIS提供了可操作的目标,以提高免疫疗法的疗效.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
08:56Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
Published on: July 12, 2022
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Treatment Resistant Cancers
Replicative Cell Senescence
